Eichberger, Jonas and Spoerl, Silvia and Spanier, Gerrit and Erber, Ramona and Taxis, Juergen and Schuderer, Johannes and Ludwig, Nils and Fiedler, Mathias and Nieberle, Felix and Ettl, Tobias and Geppert, Carol I. and Reichert, Torsten E. and Spoerl, Steffen (2022) TIGIT Expression on Intratumoral Lymphocytes Correlates with Improved Prognosis in Oral Squamous Cell Carcinoma. BIOMEDICINES, 10 (12): 3236. ISSN , 2227-9059
Full text not available from this repository. (Request a copy)Abstract
(1) Background: T-cell immunoglobulin and ITIM domain (TIGIT) is a potential immunotherapeutic target in a variety of malignant entities, and antibody-based treatments are currently under investigation in clinical trials. While promising results were observed in patients with lung cancer, the role of TIGIT in oral squamous cell carcinoma (OSCC) as a biomarker as well as a therapeutic target remains elusive. Therefore, we evaluated the role of TIGIT as a prognostic factor in OSCC. (2) Methods: Here, we describe the results of a retrospective tissue microarray (TMA) OSCC cohort. Using immunohistochemistry, TIGIT expression was correlated with overall and recurrence-free survival (OAS and RFS, respectively). Additionally, in silico analysis was performed based on the TCGA Head and Neck Squamous Cell Carcinoma (HNSCC) cohort in order to correlate patients' survival with TIGIT and CD274 (encoding for PD-L1) gene expression levels. (3) Results: Database analysis revealed a beneficial outcome in OAS for tumor patients with high intraepithelial CD3-TIGIT-expression (n = 327). Hereby, OAS was 53.9 months vs. 30.1 months for patients with lower TIGIT gene expression levels (p = 0.033). In our retrospective OSCC-TMA cohort, elevated TIGIT levels on CD3+ cells correlated significantly with improved OAS (p = 0.025) as well as distant RFS (p = 0.026). (4) Conclusions: This study introduces TIGIT as a novel prognostic factor in OSCC, indicating the improved outcome of OSCC patients relative to their increased TIGIT expression. TIGIT might provide therapeutic implications for future immunotherapy in advanced-stage OSCC patients.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | OPEN-LABEL; T-CELLS; HEAD; RECURRENT; CANCER; PEMBROLIZUMAB; 1ST-IN-HUMAN; MONOTHERAPY; ANTIBODY; T-cell immunoglobulin and ITIM domain (TIGIT); programmed death-ligand 1 (PD-L1); head and neck squamous cell carcinoma (HNSCC); oral squamous cell carcinoma (OSCC); immune checkpoint; immunotherapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Mund-, Kiefer- und Gesichtschirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 20 Feb 2024 10:17 |
| Last Modified: | 20 Feb 2024 10:17 |
| URI: | https://pred.uni-regensburg.de/id/eprint/57512 |
Actions (login required)
 |
View Item |
